Comparison · NCT03096314-927bd6db
High Dose Vitamin D Formulation vs Placebo: Hypercalcemia to Day 14
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. High Dose Vitamin D Formulation vs Placebo: Hypercalcemia to Day 14. Trial comparisons, record NCT03096314-927bd6db. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03096314-927bd6db
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0273 | 0.0163 | 0.0453 | wilson | |
| Risk in group 2 | 0.021 | 0.0118 | 0.0373 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00626 | -0.0133 | 0.0265 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.3 | 0.595 | 2.83 | log | |
| Odds ratio, group 1 over group 2 | 1.31 | 0.587 | 2.9 | log | |
| Number needed to treat, for one more participant with the outcome on High Dose Vitamin D Formulation than on Placebo | 160 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | High Dose Vitamin D Formulation | A single dose of 540,000 IU vitamin D3 will be administered within 2 hours of randomization time.~Vitamin D3: 540,000 IU vitamin D3 | 14 | 513 | OG000 |
| Group 2 | Placebo | A single, liquid enteral placebo dose administered either orally or via naso/orogastric tube will be administered within 2 hours of randomization time.~Placebo: A single, liquid enteral dose administered either orally or via naso/orogastric tube | 11 | 523 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Hypercalcemia to Day 14
- Description
As the half-life of 25OHD is approximately 2 weeks, clinically available serum or ionized calcium levels through study day 14 were collected. The number of participants with hypercalcemia was reported.
- Time frame
- up to 14 days after randomization
- Population
Source ClinicalTrials.gov
Trial
- Title
- Vitamin D to Improve Outcomes by Leveraging Early Treatment
- NCT number
- NCT03096314
- Phases
- PHASE3
- Conditions
- Acute Respiratory Distress Syndrome, Vitamin D Deficiency, Critical Illness
- Interventions
- Vitamin D3, Placebo
- Lead sponsor
- Massachusetts General Hospital
- Results first posted
- 2020-01-27
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03096314?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03096314-927bd6db